You are here: Welcome to the MPKB » Welcome to the MPKB » Resources for physicians
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

home:physicians [09.01.2019] – [Resources for physicians] sallieqhome:physicians [09.14.2022] (current) – external edit 127.0.0.1
Line 6: Line 6:
 The Marshall Protocol (MP) is the name given to a therapy devised by Professor Trevor Marshall. Based on the pathogenesis Marshall has proposed for chronic inflammatory disease, the MP is aimed at targeting bacteria, fungi, viruses, and other microbes that appear to interact to cause chronic inflammatory diseases. The Marshall Protocol (MP) is the name given to a therapy devised by Professor Trevor Marshall. Based on the pathogenesis Marshall has proposed for chronic inflammatory disease, the MP is aimed at targeting bacteria, fungi, viruses, and other microbes that appear to interact to cause chronic inflammatory diseases.
  
-Marshall and colleagues have hypothesized that chronic inflammatory diseases, including many autoimmune diseases, are caused by dysbiosis of a metagenomic microbiota: communities of microbial pathogens, many of which persist intracellularly. A [[home:publications:proal_autoimmunity_reviews_2009|recent (2009) peer-reviewed paper]] describes this [[home:pathogenesis|Pathogenesis]] in more detail.(({{pubmed>long:19393196}})) +Marshall and colleagues have hypothesized that chronic inflammatory diseases, including many autoimmune diseases, are caused by dysbiosis of a metagenomic microbiota: communities of microbial pathogens, many of which persist intracellularly. A [[home:publications:proal_autoimmunity_reviews_2009|recent (2009) peer-reviewed paper]] describes this [[home:pathogenesis|Pathogenesis]] in more detail.(({{pmid>long:19393196}})) 
  
 Supported by Autoimmunity Research Foundation, the MP has been available since 2002 and has [[home:publications:perez_congress_on_autoimmunity_2008|been used]] in a wide range of chronic inflammatory illnesses.   Supported by Autoimmunity Research Foundation, the MP has been available since 2002 and has [[home:publications:perez_congress_on_autoimmunity_2008|been used]] in a wide range of chronic inflammatory illnesses.  
Line 13: Line 13:
  
 In determining whether a patient can be successfully treated with the MP, a specific chronic disease  In determining whether a patient can be successfully treated with the MP, a specific chronic disease 
-diagnosis is not as important as the clinical assessment by an interested health care provider, the results of a [[home:starting:therapeutic_probe|therapeutic probe]], and outcome of the [[home:tests:vitdinterpretation|vitamin D metabolites blood test]].(({{pubmed>long:19758177}})) +diagnosis is not as important as the clinical assessment by an interested health care provider, the results of a [[home:starting:therapeutic_probe|therapeutic probe]], and outcome of the [[home:tests:vitdinterpretation|vitamin D metabolites blood test]].(({{pmid>long:19758177}})) 
  
-According to the Marshall Pathogenesis, chronic inflammatory disease is characterized by dysregulation of the nuclear receptor pathways which control the innate immune response. For example, the Vitamin D nuclear receptor (VDR) expresses many of the body's antimicrobial peptides (along with TLR2). In addition to down-regulation of expression of the VDR itself by many common bacteria and viruses, antagonistic microbial metabolites incrementally block ligands from activating it. Ingested vitamin D slows activity of the receptor in this same manner, preventing the body from killing the pathogens at the heart of the disease state.  That is why avoidance of ingested vitamin D (in food and supplements) is essential for the innate immune system to recover. (({{pubmed>long:19393200}})) ((Waterhouse JC, Marshall TG, Fenter B, Mangin M, Blaney G. [[home:publications:waterhouse_new_research_2006|High levels of active 1,25-dihydroxyvitamin D despite low levels of the 25-hydroxyvitamin D precursor — Implications of dysregulated vitamin D for diagnosis and treatment of Chronic Disease]]. In //Vitamin D: New Research//. +According to the Marshall Pathogenesis, chronic inflammatory disease is characterized by dysregulation of the nuclear receptor pathways which control the innate immune response. For example, the Vitamin D nuclear receptor (VDR) expresses many of the body's antimicrobial peptides (along with TLR2). In addition to down-regulation of expression of the VDR itself by many common bacteria and viruses, antagonistic microbial metabolites incrementally block ligands from activating it. Ingested vitamin D slows activity of the receptor in this same manner, preventing the body from killing the pathogens at the heart of the disease state.  That is why avoidance of ingested vitamin D (in food and supplements) is essential for the innate immune system to recover. (({{pmid>long:19393200}})) ((Waterhouse JC, Marshall TG, Fenter B, Mangin M, Blaney G. [[home:publications:waterhouse_new_research_2006|High levels of active 1,25-dihydroxyvitamin D despite low levels of the 25-hydroxyvitamin D precursor — Implications of dysregulated vitamin D for diagnosis and treatment of Chronic Disease]]. In //Vitamin D: New Research//. 
 Volume 1. Edited by: Stoltz VD. New York: Nova Science Publishers; 2006. ISBN: 1-60021-000-7.))   Volume 1. Edited by: Stoltz VD. New York: Nova Science Publishers; 2006. ISBN: 1-60021-000-7.))  
  
Line 30: Line 30:
 However, some patients do not experience significant photosensitivity during recovery. Those who do often find it more manageable several years into the therapy.  However, some patients do not experience significant photosensitivity during recovery. Those who do often find it more manageable several years into the therapy. 
  
-<note warning>Important: The Autoimmunity Research Foundation does not support or license the public use of this therapy for patients not actively participating on the Marshall Protocol study site at [[http://www.marshallprotocol.com|MarshallProtocol.com]].</note>+<note warning>Important: The Autoimmunity Research Foundation does not support or license the public use of this therapy for patients not actively participating on the Marshall Protocol study site at [[https://www.marshallprotocol.com|MarshallProtocol.com]].</note>
  
  
Line 45: Line 45:
 ==== Online forum ==== ==== Online forum ====
  
-Access to the Marshall Protocol study site is available for health professionals upon request. Health Professionals are welcome, and will be manually joined into the database after sending an email to Moderators@MarshallProtocol.com listing their desired username and password. Health professionals are granted access to the [[http://www.marshallprotocol.com/forum17/|Private Section for Health Professionals]].+Access to the Marshall Protocol study site is available for health professionals upon request. Health Professionals are welcome, and will be manually joined into the database after sending an email to Moderators@MarshallProtocol.com listing their desired username and password. Health professionals are granted access to the [[https://www.marshallprotocol.com/forum17/|Private Section for Health Professionals]].
  
  
Line 52: Line 52:
 ==== Contact Trevor Marshall directly ==== ==== Contact Trevor Marshall directly ====
  
-In addition to the [[http://www.marshallprotocol.com/forum17/|Private Section for Health Professionals]], health professionals have the option to contact Dr. Marshall at TM@AutoimmunityResearch.org or (818) 584-1201.  +In addition to the [[https://www.marshallprotocol.com/forum17/|Private Section for Health Professionals]], health professionals have the option to contact Dr. Marshall at TM@AutoimmunityResearch.org or (818) 584-1201.  
  
 To ensure success, physicians are asked to encourage their patients to carefully study this Knowledge Base. This site provides additional instructions, helpful hints, and support that will greatly ease a practitioner’s emotional support workload and smooth the patient’s path to recovery.    To ensure success, physicians are asked to encourage their patients to carefully study this Knowledge Base. This site provides additional instructions, helpful hints, and support that will greatly ease a practitioner’s emotional support workload and smooth the patient’s path to recovery.   
Line 81: Line 81:
  
    
 +<nodisp>
 ===== Notes and comments ===== ===== Notes and comments =====
  
Line 86: Line 87:
  
   * Legacy content   * Legacy content
-    * http://www.marshallprotocol.com/forum2/11458.html e73 +    * https://www.marshallprotocol.com/forum2/11458.html e73 
-    * http://www.marshallprotocol.com/view_topic.php?id=238&forum_id=2&jump_to=81703#p81703 e145+    * https://www.marshallprotocol.com/view_topic.php?id=238&forum_id=2&jump_to=81703#p81703 e145
        
  
 Trevor also mentioned that we probably do need to develop a "cover letter" which may take more time.  Trevor also mentioned that we probably do need to develop a "cover letter" which may take more time. 
  
-===== References =====+===== References =====</nodisp> 
home/physicians.1567382073.txt.gz · Last modified: 09.01.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.